Impact BioMedical, Inc. (IBO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $0.47. The rating moved from Neutral to Overbought on August 15, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$0.47
• Last changeMoved from Neutral to Overbought on August 15, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Impact BioMedical, Inc. is a very small, thinly traded healthcare issuer with limited publicly available financial and operational disclosure. Market sentiment and broader sector tailwinds for biologics and diagnostics could provide episodic support, but the company's outlook is highly dependent on opaque financing needs, potential partnership or clinical milestones, and the usual binary outcomes of early‑stage biotech. Given constrained visibility, short cash runway risk and likely dilution, price behavior will remain driven more by liquidity and newsflow than by steady fundamentals.

Key factors

• Micro‑cap biotechnology with sparse public financial disclosure and no recent EDGAR comparison available, which limits fundamental visibility.
• Limited liquidity and low float typical for sub-$1 equities increases volatility and spreads for traders and investors.
• Sector‑level tailwinds (broader demand for biologics, CRO/CDMO services and diagnostics) could create positive sentiment spillover, though indirect for this issuer.
• Current U.S. equity risk‑on tone and rotation into growth/cyclicals may briefly support speculative, small‑cap healthcare names.
• Potential need for near‑term financing or partnership activity common for small biotechs; successful capital or collaboration events would be material catalysts.

Risks

• Very limited public reporting and operating transparency — makes assessment of cash runway, revenue, or clinical status uncertain.
• High dilution risk from future equity raises; financing terms could significantly depress share value.
• Binary clinical and regulatory risk if the company is development‑stage; trial setbacks would materially reduce valuation.
• Severe liquidity and market‑microstructure risk: wide bid/ask spreads, price manipulation potential, and rapid intraday moves.
• Competitive pressures from larger well‑capitalized biotech and CRO players if company competes in therapeutic development or services.
• Potential delisting or OTC tier risk if market capitalization/filing requirements are not maintained.

Latest MarketMoodz coverage

• Cramer Backs Vertex in Mad Money Lightning Round2026-04-17
• Dow Falls 300 Points; Kroger Delivers Mixed Q42026-03-05

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.